The potential of neutrophil-derived proteins or the neutrophil-lymphocyte ratio as blood-based IBD biomarkers has been explored.21, 22, 23 The neutrophil surface expression of CD64 (encoded by FCGR1A) shows promise in relation to anti-tumor necrosis factor (TNF) treatment outcome.22 This evidence concerns the gene FCGR1A and inflammatory bowel disease.